Advanced Clinical’s Post

Unlock the power of real-world oncology insights! Dive into our Lung Cancer reports, enriched with data from community physicians and KOL insights. Explore and preview these reports now: https://lnkd.in/evNzzxdT: #LungCancer #Oncology #SolidTumors

🆕 Have you seen our new Oncology animation? If you're looking to advance your cancer therapeutic, put Veristat’s global expertise in oncology to work for you, with regulatory and clinical insights and full-service execution across the development lifecycle. Take a look at our short video to learn how we can support your Oncology needs 👇 https://bit.ly/48Mv8dU #oncology #cancertherapeutics #VeristatYouTube

MYC IHC could be crucial in tailoring immunotherapy approaches in NSCLC - Aakash Desai, MD, MPH ESMO - European Society for Medical Oncology Yash Ashara, MD Ying-Chun Lo https://lnkd.in/e_hr7nRp #Cancer #Oncology #LungCancer #OncoDaily #Oncology #lcsm

🔬 Diagnostic functional assays in oncology, a major step towards personalized medicine! 🔬 Every cancer patient requires special attention, ideally involving individualized treatment. The majority of patients today need chemotherapy to fight cancer effectively, but no test or biomarker can predict the effectiveness of treatments or combinations of treatments.  Functional tests are an important tool in the choice of chemotherapy. A recent review showed that functional tests had an efficiency of 80% to identify the most effective treatment combination (Bounaix Morand du Puch et al.,Theranostics. 2021 Sep 21;11(19): 9538-9556). https://lnkd.in/ddNPEth4 #oncology #diagnostic #functionalassay #cancer #Oncogramme

Fantastic discussion on biomarker testing and precison oncology - Rafeh Naqash Ignacio Garrido-Laguna, MD, PhD, MBA Sunnie Kim Pashtoon Kasi https://lnkd.in/dE4frPjY #Cancer #ColorectalCancer #OncoDaily #Oncology #PrecisonOncology

With #SABCS23 in full swing, hear from Stefan Faderl, VP, Therapeutic Area Head, Oncology Clinical Development, as he delves into the science behind treating #HER2 positive #breastcancer with targeted therapies: https://lnkd.in/e8eDYyyU   We recognize that a one-size-fits-all approach does not work in the treatment of #cancer, which is why we are pioneering new pathways into novel mechanisms for tumor types like breast cancer.  

Join us tomorrow, Sunday, June 2, during the ASCO Annual Meeting for a groundbreaking poster presentation between 9:00 a.m. to 12:00 p.m. Our recent study utilizing the ConcertAI Oncology Dataset has revealed promising results for patients with metastatic castration-resistant prostate cancer. Through a collaboration with Merck and AstraZeneca our real-world analysis has demonstrated that early treatment with Olaparib monotherapy could potentially enhance the duration of therapy and overall survival rates for these patients. This study underscores the importance of leveraging data to make informed treatment decisions that can ultimately improve patient outcomes. Read abstract: https://hubs.ly/Q02z9qws0 #ASCO24 #OncologyResearch #RealWorldData #OlaparibMonotherapy #PatientCare

The ProPhet test could help us to tailor immunotherapy beyond just PD-L1 expression - Edgardo S. Santos, MD, FACP, FASCO (Florida Society of Clinical Oncology) #Oncology #Cancer #Research #OncoDaily #Immunotherapy #PDL1 #ProPhet

Highly recommended this webinar relevant for any one involved in the treatment of patients with lung cancer. Learn everything about drug-drug interactions, the pros and cons of TDM, and management of toxicity, including discussion of ESMO - European Society for Medical Oncology guidelines. You are all welcome!!

Shortly commencing OV Precision Trial has now been registered at clinicaltrials.gov. It will be a landmark trial, applying precision oncological decision making using Tumor Profiler Center #TPC technologies in newly diagnosed ovarian cancer patients. HRD testing will examine the most desperate non-HRD patients, from whom we already know ow that they won’t respond to standard chemotherapy. Alternative information from TPC technologies will generate information for tge treating oncologist and allow alternative treatment decisions. #SwissGO. Swiss-GO - Designing innovative out-of-the-box trials in Gynecological Oncology